Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male/female over than 18 years old~* patient with an obstructive sleep apnea (apnea-hypopnea index \> or equal to 15)~* patient with weak or moderate hypertension (140 \<= SBP \< 180 mmHg and 90 \<= DBP \< 110 mmHg). Patient with antihypertensive monotherapy must stop their treatment and respect a washout period of at least 4 weeks before the screening visit. For patient treated by antialdosterone, the washout period will be of at least 8 weeks.~* negative pregnancy test~* ambulatory patient~* patient who have signed the informed consent form~* patient affiliated to social security~Exclusion Criteria:~* pregnant or nursing woman~* woman who refuses to use contraceptive method~* acute hepatic failure, biliary cirrhosis, cholestasis~* clearance of Cockcroft \< 30 ml/min/1.73m2~* kaliemia \>= 5.5 mmol/l~* acute hypertension (SBP\>= 180 mmHg and/or DBP \>= 110 mmHg)~* acute daytime sleepiness (Epworth rating scale \> 15)~* patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment~* known cardiovascular pathologies~* contraindication to CPAP~* allergy to Valsartan~* patient treated with lithium~* patient treated with drug(s) acting on arterial blood pressure~* patient on tutelle or curatelle~* patient kept in detention, major protected by the law, hospitalised person~* patient currently participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
- 2 (Type: EXPERIMENTAL): 8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).